CJC-1295 and Ipamorelin for body recomposition work through synchronized pulsatile growth hormone release: CJC-1295 extends endogenous GHRH half-life from 7 minutes to 6–8 days via drug affinity complex (DAC) binding to serum albumin, while Ipamorelin selectively stimulates ghrelin receptors at the pituitary without elevating cortisol or prolactin. The combination produces GH pulses 3–5x baseline amplitude, translating to sustained IGF-1 elevation of 40–80 ng/mL above pre-protocol levels within 14 days, driving preferential lipolysis in visceral adipose tissue and lean mass accretion at approximately 0.5–1.2 kg per month depending on training stimulus and caloric positioning.
This pairing has become the dominant peptide stack for body recomposition in the Enhanced Movement because it preserves endogenous GH pulsatility architecture—avoiding the flat pharmacokinetic profile of exogenous recombinant GH—while maintaining HPTA axis feedback integrity. The result: measurable fat loss concurrent with lean tissue gain, without the edema, carpal tunnel syndrome, or glucose dysregulation that accompanies pharmacological GH replacement at 4+ IU daily.
Mechanism
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation and enable covalent binding to serum albumin. The DAC modification—specifically, a maleimido-propionic acid lysine linkage—extends elimination half-life from minutes to approximately 6–8 days, creating a sustained elevation in basal GH secretion rather than discrete pulses. This produces a “raised baseline” effect: trough GH levels increase from typical nocturnal nadirs of <0.1 ng/mL to 0.3–0.6 ng/mL, while preserving endogenous pulse amplitude.
Ipamorelin is a pentapeptide ghrelin mimetic with selective binding affinity for the GHS-R1a receptor (growth hormone secretagogue receptor type 1a) on somatotroph cells in the anterior pituitary. Unlike earlier secretagogues (GHRP-6, GHRP-2), Ipamorelin demonstrates negligible activity at cortisol-releasing and prolactin-releasing pathways. The selectivity stems from its binding conformation, which activates only the Gq protein-coupled cascade leading to intracellular calcium mobilization and GH granule exocytosis. Typical single-dose administration (100 mcg subcutaneous) produces a GH pulse peaking at 90–120 minutes with amplitude 8–15 ng/mL, returning to baseline by 180 minutes.
The synergy between CJC-1295 and Ipamorelin operates through complementary pathways: CJC-1295 amplifies the GHRH tone that primes somatotrophs, while Ipamorelin delivers discrete secretagogue pulses that mimic natural GH release architecture. This dual stimulation produces GH peaks that are higher and more frequent than either compound alone, translating to greater area-under-curve GH exposure per 24-hour period. The elevated GH drives hepatic IGF-1 synthesis via JAK2-STAT5 signaling, with circulating IGF-1 mediating most anabolic and lipolytic effects in peripheral tissues.
IGF-1 binding to IGF-1R on adipocytes activates hormone-sensitive lipase (HSL) and perilipin phosphorylation, increasing lipolytic rate preferentially in visceral fat depots that express higher GH receptor density. Concurrently, IGF-1R activation in skeletal muscle stimulates mTOR pathway signaling and satellite cell proliferation, supporting protein synthesis rates that exceed breakdown when paired with resistance training and adequate leucine intake (3–4 g per meal).
Protocol
Standard body recomposition protocol: CJC-1295 DAC 2 mg subcutaneous once weekly, combined with Ipamorelin 200–300 mcg subcutaneous 2–3x daily. Inject Ipamorelin on an empty stomach (minimum 2 hours post-meal, 30 minutes pre-meal) to avoid blunted GH response from elevated glucose and free fatty acids. Optimal timing: immediately upon waking, pre-training (60 minutes before session), and before bed. The morning dose captures the natural early-morning GH pulse; pre-training dosing elevates GH during the anabolic window; bedtime administration aligns with the largest endogenous nocturnal pulse, typically occurring 60–90 minutes post-sleep onset.
CJC-1295 DAC injection can occur any day of the week at any time, as its long half-life creates stable plasma levels. Most users inject Sunday evening for convenience and consistent weekly scheduling. Reconstitute both peptides with bacteriostatic water: 2 mL into a 2 mg CJC vial yields 1 mg/mL concentration; 2 mL into a 5 mg Ipamorelin vial yields 2.5 mg/mL (each 0.1 mL = 250 mcg). Store reconstituted peptides refrigerated at 2–8°C; CJC-1295 remains stable for 30 days, Ipamorelin for 21 days.
Cycle duration: 12–16 weeks for initial body recomposition phases. The IGF-1 elevation plateaus around week 6–8, with continued fat loss and lean gain observable through week 12. Some practitioners run continuous protocols for 6+ months without apparent receptor desensitization, though periodic growth hormone cycling (4 weeks off after 16 weeks on) may preserve long-term responsiveness—though definitive data on GHRH/ghrelin receptor downregulation with these specific peptides remains limited.
Stacking considerations: synergistic compounds include testosterone base (150–300 mg weekly) to maintain anabolic signaling and prevent GH-induced lipolysis from mobilizing more fatty acids than can be oxidized, leading to ectopic lipid deposition. Metformin 500–1000 mg daily mitigates the insulin resistance that can develop from chronic GH elevation. T3 at 25–50 mcg daily addresses the GH-mediated reduction in peripheral T4-to-T3 conversion, maintaining metabolic rate and fat oxidation capacity.
Caloric positioning: body recomposition is most pronounced in a maintenance-to-slight-deficit range (10–15% below calculated TDEE) with protein intake at 2.2–2.8 g/kg bodyweight. The GH/IGF-1 axis preserves lean mass even in caloric deficits that would otherwise trigger catabolism, while simultaneously increasing lipid mobilization and oxidation rates. Training stimulus must include progressive overload resistance work 4–5x weekly to capitalize on the heightened muscle protein synthesis potential.
Monitoring
Baseline bloodwork before protocol initiation: IGF-1, fasting glucose, HbA1c, lipid panel, prolactin, cortisol (8 AM sample), thyroid panel (TSH, free T3, free T4). IGF-1 is the primary monitoring marker for protocol efficacy: pre-protocol levels typically range 150–250 ng/mL for adults aged 25–45. Target on-protocol elevation to 280–350 ng/mL, indicating adequate GH pulsatility without supraphysiological excess.
Retest at week 2 (IGF-1 only, confirms dosing adequacy), week 6 (full panel), and week 12 (full panel). IGF-1 below 250 ng/mL at week 2 suggests underdosing, reconstitution error, or degraded peptide; consider increasing Ipamorelin frequency to 3x daily or verifying CJC-1295 product authenticity via third-party mass spectrometry (expected molecular weight 3647.28 Da).
Fasting glucose should remain <100 mg/dL; values creeping above 105 mg/dL indicate developing insulin resistance, addressed by adding berberine 500 mg 3x daily or metformin as above. HbA1c monitors cumulative glycemic exposure; remain below 5.5%. Elevations above 5.7% warrant carbohydrate restriction or SGLT2 inhibitor addition (empagliflozin 10 mg daily).
Prolactin should remain stable <15 ng/mL in males; increases above 20 ng/mL—though rare with Ipamorelin's selectivity—require dopamine agonist intervention (cabergoline 0.25 mg twice weekly). Thyroid panel monitoring addresses GH-induced reduction in deiodinase activity: free T3 declining below 3.0 pg/mL or reverse T3 climbing above 20 ng/dL indicates need for exogenous T3 supplementation.
Symptomatic monitoring: mild fluid retention (tight rings, morning facial puffiness) is common in weeks 1–3 as GH increases sodium retention via renal tubule effects; this typically self-resolves. Persistent edema beyond week 4 suggests excessive dosing; reduce Ipamorelin to 2x daily. Carpal tunnel symptoms (nocturnal hand numbness, thenar weakness) indicate nerve compression from fluid accumulation in the carpal tunnel; dose reduction plus vitamin B6 (100 mg daily) and wrist splinting at night provides relief. Joint discomfort without swelling suggests ligament/tendon growth adaptation; reduce training volume 15–20% for two weeks.
Risks and Mitigation
Insulin resistance and hyperglycemia: GH antagonizes insulin signaling via direct interference with IRS-1 phosphorylation and increased hepatic glucose output. Monitor fasting glucose weekly with home glucometer; implement time-restricted feeding (8-hour eating window), reduce dietary carbohydrates below 150 g daily, add metformin 500 mg with largest meal, titrating to 1000 mg if glucose remains elevated. Berberine provides alternative AMPK activation if metformin causes GI distress.
Hypothyroidism symptoms despite normal TSH: GH reduces peripheral T4-to-T3 conversion through deiodinase enzyme downregulation. Manifests as cold intolerance, cognitive sluggishness, reduced training recovery despite adequate sleep. Add T3 (liothyronine) 25 mcg upon waking; retest free T3 at two weeks, targeting mid-to-upper reference range (3.5–4.2 pg/mL). Do not rely on TSH alone for dosing decisions.
Injection site reactions: erythema, induration, or subcutaneous nodules at injection sites occur in approximately 8% of users, typically from inadequate reconstitution technique or injection into same site repeatedly. Rotate injection sites across abdomen, anterior thighs, and deltoids on at least 10-site rotation. Ensure complete peptide dissolution before injection—gently swirl vial, never shake. Consider switching from bacteriostatic water to sterile water for injection if reactions persist.
Tumor growth theoretical concern: IGF-1 promotes cell proliferation; individuals with active malignancy should avoid all GH secretagogues. For cancer survivors beyond five-year remission, the risk-benefit calculation becomes individual. No evidence suggests GH/IGF-1 initiate tumorigenesis in healthy tissue, but existing microscopic disease could theoretically accelerate. Baseline cancer screening appropriate to age and family history before protocol initiation.
Comparisons
CJC-1295/Ipamorelin versus recombinant human growth hormone (rhGH): rhGH at 2–4 IU daily provides consistent, flat GH levels throughout the day, eliminating natural pulsatility. This produces more pronounced fat loss (1.5–2.5 kg per month) but significantly higher rates of insulin resistance (fasting glucose >110 mg/dL in 40% of users at 4+ IU daily), edema requiring diuretic intervention (20–30% incidence), and cost approximately 3–4x higher ($400–600 monthly versus $120–180 for peptide stack). The peptide combination preserves pulsatile architecture, reducing side effect burden while delivering 60–70% of rhGH’s body composition changes.
CJC-1295/Ipamorelin versus MK-677 (ibutamoren): MK-677 is an orally bioavailable ghrelin mimetic dosed 20–25 mg nightly, producing sustained GH elevation via continuous receptor occupation. This continuous stimulation increases prolactin (15–20% of users exceed 25 ng/mL) and causes significant appetite stimulation through ghrelin pathway activation—problematic for fat loss phases. MK-677 elevates IGF-1 approximately 40–60 ng/mL versus 60–90 ng/mL with the CJC/Ipamorelin stack. The injectable peptide combination provides superior control over pulsatility timing and avoids the hunger and lethargy many report with MK-677 protocols.
CJC-1295 DAC versus CJC-1295 without DAC (Modified GRF 1-29): the non-DAC version has a 30-minute half-life, requiring 3–4x daily dosing synchronized with Ipamorelin injections for pulsatile peaks. This creates sharper GH spikes but demands more frequent injections. Body composition outcomes appear equivalent with both versions when total weekly dosing is normalized; DAC version offers convenience, non-DAC offers more control over pulse timing and slightly lower injection-site reaction incidence.
Common Mistakes
Injecting Ipamorelin post-meal: elevated glucose and circulating fatty acids from recent food intake attenuate GH pulse amplitude by 40–60%. The secretagogue must encounter a fasted metabolic state to achieve full effect. Maintain minimum 2-hour fast pre-injection, 30-minute fast post-injection before eating.
Inadequate protein intake: elevated GH/IGF-1 increases muscle protein synthesis capacity, but without sufficient substrate (amino acids), the anabolic potential goes unrealized. Minimum 2.2 g/kg daily, distributed across 4–5 meals with 30–40 g per meal. Leucine threshold of 3 g per meal maximizes mTOR activation.
Ignoring insulin sensitivity markers: users chase IGF-1 elevation without monitoring glucose, then develop hyperglycemia that undermines body composition goals and creates long-term metabolic damage. Test fasting glucose weekly; implement countermeasures at first sign of elevation above 100 mg/dL, not after HbA1c climbs to prediabetic range.
Reconstitution with incorrect diluent: using sterile saline instead of bacteriostatic water reduces peptide stability; using tap water introduces endotoxins. Only bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection is appropriate. Verify diluent source from pharmaceutical supplier.
Expecting results without training stimulus: GH/IGF-1 create permissive anabolic conditions, but lean mass accretion requires mechanical tension and progressive overload. The peptides enhance recovery and protein synthesis, allowing higher training frequency and volume—but won’t build muscle without resistance training driving the adaptation signal.
Bottom Line
- CJC-1295 DAC 2 mg weekly + Ipamorelin 200–300 mcg 2–3x daily on empty stomach produces IGF-1 elevation of 40–80 ng/mL, driving 0.5–1.2 kg lean mass gain monthly with concurrent fat loss
- Monitor fasting glucose weekly, full bloodwork at weeks 2, 6, and 12; add metformin if glucose exceeds 100 mg/dL, T3 if free T3 drops below 3.0 pg/mL
- 12–16 week cycles with optional 4-week break preserve responsiveness; stack with testosterone base 150–300 mg weekly for optimal results
- Inject Ipamorelin minimum 2 hours post-meal; timing around waking, training, and sleep captures natural GH pulse architecture
- Protein 2.2–2.8 g/kg daily plus progressive resistance training required to capitalize on elevated anabolic signaling; peptides amplify but don’t replace training stimulus